Effectiveness and Safety of Sequential Triple Combination Therapy (Amlodipine/Losartan/Chlorthalidone) in Korean Patients With Hypertension
Recruiting · NCT07784296 · Observational (researchers observe without assigning treatment) · Lead sponsor: Hanmi Pharmaceutical Company Limited
View the official record on ClinicalTrials.gov →Interventions studied
AMOPREL TAB 1.67/16.67/4.17mg
What this trial is about
A multicenter, prospective, non-interventional, observational study to evaluate effectiveness and safety of sequential triple combination therapy (amlodipine/losartan/chlorthalidone) in Korean patients with hypertension
Who can take part
Age range
No age limits stated
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not specified
Study type
Observational (researchers observe without assigning treatment)
Inclusion criteria
- Korean patients aged 19 years or older diagnosed with hypertension
- Individuals newly diagnosed with hypertension or currently taking a single antihypertensive drug
- Individuals for whom administration of Amoprel tablets has been determined based on the researcher's medical judgment
- Individuals who have heard an explanation of this study and have voluntarily given written consent to participate in the study
Exclusion criteria
- Individuals falling under the contraindications listed in the precautions for use of Amoprel Tab. or Amozartan Plus Tab.
- Pregnant women, women who may be pregnant, and nursing mothers
- Individuals currently participating in an interventional study
- Individuals deemed unsuitable for participation in this study by the researcher for other reasons
Where it is running
1 location listed.
- Yongin Severance Hospital - Gyeonggi-do, South Korea